Halberd Corp
OTC:HALB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Halberd Corp
Common Shares Outstanding
Halberd Corp
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Halberd Corp
OTC:HALB
|
Common Shares Outstanding
$65.4m
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Shares Outstanding
$539m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Common Shares Outstanding
$132.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
Common Shares Outstanding
$197m
|
CAGR 3-Years
30%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Common Shares Outstanding
$43.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Common Shares Outstanding
$394m
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Halberd Corp
Glance View
Halberd Corp. is a development stage company, researches and develops antibodies and devices for the prevention, detection, and treatment of Covid-19 through laboratory, hospital, and clinical trials. The company is headquartered in Jackson Center, Pennsylvania. The company went IPO on 2009-06-12. The firm is a research-based company that intends to discover and develop medical treatments for a range of diseases. The firm's extracorporeal treatment is applicable for hard-to-cure blood-borne and neurologic diseases, such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. The company is also developing treatment for coronavirus disease of 2019 (Covid-19), obesity, such as high blood pressure, diabetes, heart disease, stroke, and cancer.
See Also
What is Halberd Corp's Common Shares Outstanding?
Common Shares Outstanding
65.4m
USD
Based on the financial report for Jul 31, 2012, Halberd Corp's Common Shares Outstanding amounts to 65.4m USD.
What is Halberd Corp's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
36%
Over the last year, the Common Shares Outstanding growth was 148%. The average annual Common Shares Outstanding growth rates for Halberd Corp have been 36% over the past three years .
